SecBot SecBot

SUPN

Supernus, Inc.
Nasdaq· CIK 0001625297
$28.21 +0.06 (+0.21%)
Nov 4 4:00 PM ET · prev $28.15
Market cap
$2.4B
Mid cap
Median target
🔒 Subscribers only
1 year
−12.0%
from $32.05 · Nov 5
30 days
−21.6%
from $35.99
52-week range
$28.15–41.83
−33% from high · low Nov 3
Avg volume 20D
3.51M
Nov 3 spike 9.05M
Short interest
4.04M
≈7.0% of shares · −18.9%
Days to cover
4.9
at average volume
Insider net
$0
no open-market trades · since Nov 2
New fund stakes
0
Q2 2026 13F · 1 exit
Filing reports
38
analyzed by SecBot
Congress trades
1
disclosed
SecBot read MIXED 20 reports · 90 days
Balance 3 bearish · 1 bullish · 1 mixed · 15 neutral oldest → newest, height = score
Avg score ·High conf. 13/20
Strongest BEARISH Supernus Pharmaceuticals filed an 8-K Item 3.01 notifying Nasdaq of the completion of a merger on November…
All reports →

Price

Daily candles with volume. Callouts mark insider and congressional trades, rating changes, 13F stakes, reports, catalysts, court and regulator actions, Reddit spikes and short-interest jumps. Hover one for the details (tap on phones).

Signal stack

Where each data set points today.

  • InsidersNO TRADES

    No open-market buys or sells since Nov 2. Recent filings are awards, exercises and tax withholding.

  • InstitutionsMIXED

    Q2 2026: 26 added (0 new), 18 trimmed or exited.

  • Short sellersCOVERING

    Short interest −18.9% to 4.04M shares. 4.9 days to cover, ≈7.0% of shares.

  • TrendDOWNTREND

    19% below its 50-day average. New closing low $28.15 on Nov 3.

Who's buying

13F· Q2 2026
0
new positions
1
exit
FundMoveSharesValue
Qube Research & Technologies LtdADD922,166$42.9M
Woodline Partners LPADD708,276$32.9M
Aberdeen Group plcADD453,206$21.1M
SCHRODER INVESTMENT MANAGEMENT GROUPDOUBLED368,017$17.2M
Freestone Grove Partners LPTRIM316,398$14.7M
FMR LLCADD309,091$14.4M
Man Group plcDOUBLED156,422$7.3M
BNP PARIBAS FINANCIAL MARKETSDOUBLED148,579$6.9M

Quarterly 13F filings are due 45 days after each quarter ends.

The Street

last action Jul 2026

Fresh Price Targets

Analyst price targets updated within the last 24 hours are for subscribers only.

Subscribe for Full Access
Recent actions
DateFirmActionRating
Jul 9, 2026Cantor Fitzgerald
MAINTAIN
MAINTAINOverweight
Congressional trades
SUPN trades disclosed by members of Congress, with disclosure delay.
1 members · 1 buys / 0 sells
DateMemberType AmountDisclosed
Mar 3, 2026 Gilbert CisnerosDHouse Supernus Pharmaceuticals Inc BUY $1K–$15K Apr 7, 2026 +35d

Insider ledger

Form 4
🔒 Subscribers only
50 transactions
DateInsiderTypeValue
Nov 2, 2026🔒 Fresh data, subscribers only
Nov 2, 2026
OTHER
Nov 2, 2026🔒 Fresh data, subscribers only
Nov 2, 2026
OTHER
Nov 2, 2026🔒 Fresh data, subscribers only
Nov 2, 2026
OTHER
Nov 2, 2026🔒 Fresh data, subscribers only
Nov 2, 2026
OTHER
Nov 2, 2026🔒 Fresh data, subscribers only
Nov 2, 2026
OTHER
Nov 2, 2026🔒 Fresh data, subscribers only
Nov 2, 2026
OTHER
Nov 2, 2026🔒 Fresh data, subscribers only
Nov 2, 2026
OTHER
Nov 2, 2026🔒 Fresh data, subscribers only
Nov 2, 2026
OTHER

Earnings setup

Estimates

Revision history: 🔒 Fresh data, subscribers only

PeriodEPS est.Range30D rev.Revenue
Current Q🔒 Fresh data, subscribers only
Next Q🔒 Fresh data, subscribers only
Current FY🔒 Fresh data, subscribers only
Next FY🔒 Fresh data, subscribers only

Short side

FINRA· Oct 15, 2026
4,043,677
shares short
-18.9%
vs prior settlement
4.9
days to cover
≈7.0%
of shares outstanding
Trading halts
Oct 30, 2026Info RequestedNot resumed
Recent activity
The latest filings, insider trades, analyst actions, press and options flow, newest first.
Nov 4, 2026 SEC
🔒 Fresh report (last 24h), subscribers only
Nov 4, 2026 SEC
🔒 Fresh report (last 24h), subscribers only
Nov 4, 2026 SEC
🔒 Fresh report (last 24h), subscribers only
Nov 2, 2026 Press
Supernus Pharmaceuticals and Indivior Pharmaceuticals completed their merger, creating Supernus, Inc., a combined CNS…
Impact 6/10
Nov 2, 2026 M&A
Supernus and Indivior Complete Merger Creating a Diversified CNS Biopharmaceutical Leader
ROCKVILLE, Md., Nov. 02, 2026 (GLOBE NEWSWIRE) -- Supernus, Inc. (Nasdaq: SUPN) 1 today announced th
Nov 2, 2026 Insider
🔒 Fresh data, subscribers only
Nov 2, 2026 Insider
🔒 Fresh data, subscribers only
Nov 2, 2026 Insider
🔒 Fresh data, subscribers only
Catalysts
Scheduled dates and disclosed events: earnings, FDA and trial readouts, halts, press releases. Colored dot = impact.
Recent
Nov 2, 2026
M&A
Supernus and Indivior Complete Merger Creating a Diversified CNS Biopharmaceutical Leader
ROCKVILLE, Md., Nov. 02, 2026 (GLOBE NEWSWIRE) -- Supernus, Inc. (Nasdaq: SUPN) 1 today announced the successful completion of the merger between…
Oct 30, 2026
Trading halt
Trading Halt: SUPN · T12 (Additional Information Requested)
Supernus Pharmaceuticals, Inc. | Market: NASDAQ | Code: T12 (Additional Information Requested)
Oct 29, 2026
Earnings
Supernus Announces Third Quarter 2026 Financial Results
ROCKVILLE, Md., Oct. 29, 2026 (GLOBE NEWSWIRE) -- Supernus Pharmaceuticals, Inc. (Nasdaq: SUPN), a biopharmaceutical company focused on developing…
Oct 29, 2026
Earnings result
SUPN Q3 2026 Earnings: EPS $0.93 (+65.8% vs est)
Oct 26, 2026
Enforcement
US WorldMeds Partners, LLC v. Supernus Pharms., Inc.
Court ruling (delsuperct), Docket: N25C-07-121 KMM CCLD

SecBot reports

38 filings · 1 press release · 9 bullish · 4 bearish · 2 mixed · 23 neutral
All SUPN filing & press-release reports (39)